



Dysport[®] (abobotulinumtoxinA) – Expanded indication

- On September 26, 2019, [Ipsen Biopharmaceuticals](#) announced the [FDA approval](#) of [Dysport \(abobotulinumtoxinA\)](#), for the treatment of upper limb spasticity in pediatric patients 2 years of age and older, excluding spasticity caused by cerebral palsy.
 - Dysport was previously approved for the treatment of lower limb spasticity in pediatric patients 2 years of age and older.
- Dysport is also approved for cervical dystonia in adults, glabellar lines in adults less than 65 years of age, and spasticity in adults.
- The approval of Dysport for the expanded indication was based on a double-blind, low-dose controlled study in 208 pediatric patients 2 years of age and older with upper limb spasticity. Patients received Dysport 16 units/kg, Dysport 8 units/kg, or Dysport 2 units/kg. The primary efficacy endpoint was the mean change from baseline in Modified Ashworth Score (MAS) in the primary targeted muscle group (PTMG) at week 6.
 - Dysport showed statistically significant improvements in the primary endpoint, with doses of 8 units/kg and 16 units/kg vs. the low dose Dysport (2 Units/kg) (-2.0, -2.3 and -1.6, respectively).
- Dysport carries a boxed warning for distant spread of toxin effect.
- The most common adverse reactions ($\geq 10\%$) with Dysport use in pediatric patients with upper limb spasticity were upper respiratory tract infection and pharyngitis.
- The recommended dose of Dysport for the treatment of upper limb spasticity (excluding spasticity caused by cerebral palsy) in pediatric patients is 8 units/kg to 16 units/kg intramuscularly per limb. The maximum recommended total dose administered per treatment session must not exceed 16 units/kg or 640 units, whichever is lower.
- Refer to the Dysport drug label for complete dosing and administration recommendations for this indication and all its other indications.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.